Skip to main content
. 2016 Jun 30;7(31):49334–49348. doi: 10.18632/oncotarget.10340

Figure 2. Kaplan-Meier survival curves for disease-free survival according to the results of V-ATPase V1E1 immunostaining.

Figure 2

(A) Kaplan-Meier curves showing disease-free survival among patients with ESCC on the basis of V-ATPase V1E1 expression status; V-ATPase V1E1 (IHC score = 0, n = 12; IHC score=1, n = 72; IHC score =2, n = 60; IHC score =3, n = 16). (B) Disease-free survival among patients with ESCC on the basis of V-ATPase V1E1 expression status at stage I + II (low V1E1, IHC score < 2, n = 47; high V1E1, IHC score ≥ 2, n = 34). (C) Disease-free survival among patients with ESCC on the basis of V-ATPase V1E1 expression status at stage III + IV (low V1E1, IHC score < 2, n = 37; high V1E1, IHC score ≥ 2, n = 42). (D) Disease-free survival among patients with ESCC on the basis of V-ATPase V1E1 expression status; low V1E1 (IHC score < 2, n = 84) and high V1E1 (IHC score ≥ 2, n = 76). P values are from Log-Rank test.